论文部分内容阅读
目的:探讨肺癌患者凝血功能指标检测的变化及临床意义。方法:采用法国STAGO公司生产的STA- R全自动凝血/纤溶分析仪测定148例健康体检者和106例肺癌患者的血浆凝血酶原时间(PT)、部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(Fib),同时计数血小板(PLT)。结果:肺癌组与正常组比较PT、TT差异无显著性(P>0.05),APTT结果较正常组延长差异有显著性(P<0.05),Fib、PLT结果较正常组明显增高差异有非常显著性(P<0.01)。不同肺癌临床分期(Ⅰ期-Ⅲ期与Ⅳ期)比较凝血指标差异无显著性(P>0.05)。结论:APTT结果延长,提示肺癌患者存在凝血功能紊乱,Fib、PLT结果增高,可致肺癌患者血栓形成和癌细胞远处转移,因此,凝血功能指标监测对肺癌患者治疗具有一定的指导意义。
Objective: To investigate the changes of coagulation function in lung cancer patients and its clinical significance. Methods: The plasma concentrations of prothrombin time (PT), partial thromboplastin time (APTT), coagulation and blood coagulation in 148 healthy subjects and 106 patients with lung cancer were measured by STA-R automatic coagulation / fibrinolytic analyzer manufactured by STAGO in France. Enzyme time (TT), fibrinogen (Fib), while platelet count (PLT). Results: There was no significant difference in PT and TT between the lung cancer group and the normal group (P> 0.05). The APTT result was significantly longer than that of the normal group (P <0.05). The Fib and PLT results were significantly higher than those of the normal group (P <0.01). There was no significant difference in coagulation index between different clinical stage of lung cancer (stage Ⅰ-Ⅲ and stage Ⅳ) (P> 0.05). CONCLUSION: Prolonged APTT results suggest coagulation disorders in patients with lung cancer and increased Fib and PLT results in thrombosis and distant metastasis of lung cancer patients. Therefore, the monitoring of coagulation parameters may be of guiding significance for the treatment of patients with lung cancer.